The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the fixed-dose combination of latanoprost and netarsudil (Roclanda).
The ophthalmic solution is indicated to decrease elevated intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil fails, according to an EMA news release.
Reference:
https://www.medscape.com/viewarticle/941062?src=rss